Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Song

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Dermatologic Clinics|May 25, 2024
The Psoriasis Treatment Pipeline: An Overview and UpdateJason E Hawkes, Miriam Al-Saedy, Nicole Bouché, et al.
BJU International|June 8, 2007
Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostateAnthony J Schaeffer, Francesco Montorsi, Vincenzo Scattoni, et al.
Journal of the American Academy of Dermatology|April 26, 2026
Response to "Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX"Harrison P Nguyen, Eingun James Song, Edward Ted Lain, et al.
Breast Cancer (Dove Medical Press)|December 21, 2016
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter studyShannon Puhalla, Sharon Wilks, Adam M Brufsky, et al.
Cancer Chemotherapy and Pharmacology|June 14, 2019
A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancerSanjay Goel, Umang Swami, Kirushna Kumar, et al.
Journal of Biopharmaceutical Statistics|August 10, 2022
The win odds: statistical inference and regressionJames Song, Johan Verbeeck, Bo Huang, et al.
Analytical Chemistry|March 31, 2025
Novel Native Reversed-Phase Liquid Chromatography (nRPLC)/MS for Antibody-Drug Conjugates (ADCs) Characterization and Drug-Antibody Ratio (DAR) AssessmentFengfei Ma, A Carl Sanchez, James Song, et al.
Dermatology and Therapy|April 15, 2025
Management of Challenging Psoriasis Clinical ScenariosLinda Stein Gold, Andrew Alexis, Brad P Glick, et al.
Breast Cancer : Basic and Clinical Research|July 12, 2016
Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast CancerChris Twelves, Ahmad Awada, Javier Cortes, et al.
Postgraduate Medicine|August 12, 2009
A 'gap' between physician and patient assessment of symptom severity in acute cystitis?: a multicenter trial of women treated with extended-release ciprofloxacinMary Kay Tucker, Frank D Brigio, G Alexis Sirotenko, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Dermatologic Clinics|May 25, 2024
The Psoriasis Treatment Pipeline: An Overview and UpdateJason E Hawkes, Miriam Al-Saedy, Nicole Bouché, et al.
BJU International|June 8, 2007
Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostateAnthony J Schaeffer, Francesco Montorsi, Vincenzo Scattoni, et al.
Journal of the American Academy of Dermatology|April 26, 2026
Response to "Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX"Harrison P Nguyen, Eingun James Song, Edward Ted Lain, et al.
Breast Cancer (Dove Medical Press)|December 21, 2016
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter studyShannon Puhalla, Sharon Wilks, Adam M Brufsky, et al.
Cancer Chemotherapy and Pharmacology|June 14, 2019
A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancerSanjay Goel, Umang Swami, Kirushna Kumar, et al.
Journal of Biopharmaceutical Statistics|August 10, 2022
The win odds: statistical inference and regressionJames Song, Johan Verbeeck, Bo Huang, et al.
Analytical Chemistry|March 31, 2025
Novel Native Reversed-Phase Liquid Chromatography (nRPLC)/MS for Antibody-Drug Conjugates (ADCs) Characterization and Drug-Antibody Ratio (DAR) AssessmentFengfei Ma, A Carl Sanchez, James Song, et al.
Dermatology and Therapy|April 15, 2025
Management of Challenging Psoriasis Clinical ScenariosLinda Stein Gold, Andrew Alexis, Brad P Glick, et al.
Breast Cancer : Basic and Clinical Research|July 12, 2016
Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast CancerChris Twelves, Ahmad Awada, Javier Cortes, et al.
Postgraduate Medicine|August 12, 2009
A 'gap' between physician and patient assessment of symptom severity in acute cystitis?: a multicenter trial of women treated with extended-release ciprofloxacinMary Kay Tucker, Frank D Brigio, G Alexis Sirotenko, et al.
Pageof 10